In addition, FDG-PET has wide application across all forms of degenerative dementia because it contains useful features across the entire spectrum of aetiologies beyond amyloid- and tau-associated conditions.22 Nevertheless, measuring tau pathology is integral to the diagnosis and prognosis of the Alzheimer’s disease continuum and increasing the accessibility of tau-PET has potential to enable a greater role in research and clinical applications in the future.23 The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.